[ad_1] Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response SAN DIEGO and CALGARY, Alberta, Nov. 9, 2023 /PRNewswire/ — Oncolytics Biotech® Inc.…
[ad_1] Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response SAN DIEGO and CALGARY, Alberta, Nov. 9, 2023 /PRNewswire/ — Oncolytics Biotech® Inc.…